Latest Safety News

Immutep’s combination of eftilagimod alfa (efti) and KEYTRUDA® delivers a striking 17.6-month median overall survival in head and neck cancer patients with low PD-L1 expression, a group with limited treatment options.

SenSen Networks has extended its contract with Brisbane City Council for kerb management and enforcement solutions, including a large-scale rollout of its innovative SenPIC technology, in a deal valued at an estimated $8 million over four years.

Nyrada Inc. has cleared the Safety Review Committee’s scrutiny for its Phase I clinical trial, progressing to the third dosing cohort of its promising neuroprotective and cardioprotective drug candidate NYR-BI03.

Saferoads Holdings has finalised the sale of its Road Safety Rentals assets, repaid all related debts, and announced a fully franked 10 cent special dividend for shareholders.

Dimerix Limited has announced a US licensing transaction for its Phase 3 asset DMX-200 targeting FSGS, alongside progress updates on its clinical trial. The move underscores the company’s push to address a rare kidney disease with no approved therapies.

Dimerix has inked an exclusive US licensing agreement with Amicus Therapeutics for DMX-200, a promising Phase 3 treatment for FSGS, unlocking $30 million upfront and up to $560 million in milestones.

Pilot Energy confirms regulatory compliance and operational progress at the Head Field, advancing the repurposing of Cliff Oil infrastructure into a carbon storage facility as part of the Mid West Clean Energy Project.

Imricor Medical Systems has initiated its first MRI-guided atrial flutter ablation procedures at Semmelweis University in Budapest, marking a significant expansion of its real-time MRI technology in Europe.

Buxton Resources has won up to A$180,000 in government co-funding to kickstart drilling at its 100%-owned Madman Project in Western Australia, advancing exploration in a promising but underexplored gold-copper region.

EMU NL’s latest quarterly report reveals promising copper exploration parallels with Canada’s largest open-pit mine, a renewed gold project strategy, and significant corporate restructuring amid shareholder disputes.

Macro Metals Limited has secured $2 million from a strategic placement to Paramount Earthmoving, advanced exploration across multiple Pilbara projects, and entered a second majority Indigenous-owned joint venture, positioning itself for growth in mining services.

Recce Pharmaceuticals reports strong Phase II clinical trial results for its topical anti-infective R327G, achieving a 93% efficacy rate in treating ABSSSI, alongside a significant capital raise to fund upcoming Phase III trials.